JJP Biologics to Present Nebaprubart Data at Two European Dermatology Conferences
JJP Biologics will share findings on its anti-CD89 drug nebaprubart at conferences in Germany and Austria in late September 2026.
Warsaw-based clinical-stage biotech JJP Biologics announced Monday that data on its investigational drug nebaprubart will be showcased at two major European scientific gatherings within days of each other, signaling growing interest in the compound's potential to treat Linear IgA Dermatosis, a rare autoimmune blistering skin condition.
Nebaprubart, described by the company as a first-in-class anti-CD89 antagonist, targets immune pathways implicated in autoimmune diseases and certain cancers. The drug's mechanism — blocking the CD89 receptor to interrupt aberrant immune signaling — represents a novel therapeutic approach for conditions that currently have limited treatment options.
Read more Aon Unveils $2.5B Insurance Program for Gas Power Projects →
The first presentation will take place as an oral session at the IPPF Scientific Symposium on Pemphigus and Pemphigoid, scheduled for September 28-29 in Lübeck, Germany. Days later, a poster presentation is planned at the European Academy of Dermatology and Venereology Congress, running September 30 through October 3 in Vienna, Austria — one of the field's most prominent annual gatherings.
The back-to-back conference appearances provide JJP Biologics an opportunity to build visibility among European dermatology specialists and potential collaborators at a critical stage of the drug's development. For patients with Linear IgA Dermatosis, a disease with few approved therapies, advances in targeted biologics such as nebaprubart could represent a meaningful clinical step forward, though the drug remains investigational.
Continue reading at GlobeNewswire - Industry News on Financial Services.
